Risankizumab

(Skyrizi)

Risankizumab

Drug updated on 11/14/2023

Dosage FormInjection (subcutaneous: 75 mg/0.83 mL, 150 mg/mL)
Drug ClassInterleukin-23 antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
  • For the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for active psoriatic arthritis in adults.
  • For the treatment of moderately to severely active Crohn's disease in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Skyrizi (risankizumab-rzaa) Prescribing Information.2022AbbVie Inc., North Chicago, IL

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Risankizumab for previously treated moderately to severely active Crohn's disease.2023NICE
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.2022Cochrane Database of Systematic Reviews
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs.2022NICE
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.2022Rheumatology
Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis.2022Dermatology and Therapy
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.2022Journal of Dermatological Treatment
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.2021Journal of the German Society of Dermatology
Efficacy and safety of risankizumab in moderate to severe psoriasis: a systematic review and meta‐analysis. 2021Dermatologic Therapy
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data.2021Journal of the American Academy of Dermatology
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. 2021Dermatology and Therapy
Short-term efficacy of biologic therapies in moderate to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. 2021Dermatology and Therapy
Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review.2021Journal of the European Academy of Dermatology & Venerology
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.2020Journal of the European Academy of Dermatology and Venereology
Short-term effectiveness of biologics in patients with moderate-to -severe plaque psoriasis: a systematic review and network meta-analysis.2020Journal of Dermatological Science
Efficacy and safety of risankizumab in moderate to severe psoriasis: a systematic review and meta‐analysis.2020Dermatologic Therapy
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. 2020Journal of Dermatological Treatment
Clinical review report: risankizumab (skyrizi) (AbbVie).2019CADTH
Risankizumab for treating moderate to severe plaque psoriasis.2019NICE
CHMP assessment report: skyrizi. 2019EMA
Targeted immunomodulators for the treatment of Moderate-to-Severe plaque psoriasis: effectiveness and value. 2018ICER
Emerging therapies in psoriasis: a systematic review.2018Cutis

Clinical Practice Guidelines

Document TitleYearSource
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.2019Journal of the American Academy of Dermatology